Samvat 2083's first trading hour belonged to one stock. While the Sensex and Nifty both ended Sunday's one-hour Muhurat session marginally lower, Divi's Laboratories jumped more than 8% to a fresh 52-week high of ₹11,194 on the NSE — a day after the pharma major reported a 64% jump in quarterly profit.

Quick Answer

Divi's Laboratories reported Q2 FY27 consolidated net profit of ₹1,127 crore, up 64% from ₹689 crore a year ago, on revenue of ₹3,676 crore, up 35%. EBITDA rose 76% to ₹1,566 crore. Shares jumped over 8% to a 52-week high of ₹11,194 in Sunday's Muhurat session, while the Sensex and Nifty ended marginally lower.

The quarter in five numbers

Divi's Laboratories' board approved the results on Saturday, 7 November 2026. The statutory auditors issued an unmodified limited-review conclusion on the interim results. All figures below are consolidated, for the quarter ended 30 September 2026: - Net profit: ₹1,127 crore, up 63.57% year on year from ₹689 crore in Q2 FY26 — and up 24.94% from ₹902 crore in Q1 FY27. - Revenue from operations: ₹3,676 crore, up 35.4% from ₹2,715 crore a year ago — and up 19.35% from ₹3,080 crore last quarter. - EBITDA: ₹1,566 crore, up 76% from ₹888 crore a year ago. Operating margin: 42.60%. - Profit before tax: ₹1,505 crore, up 65% from ₹912 crore a year ago. - Total income: ₹3,770 crore, up 31.8% from ₹2,860 crore a year ago. For the first half of FY27, net profit was ₹2,029 crore against ₹1,234 crore in the same period last year. Brokerage Elara Capital noted that revenue, EBITDA and profit came in 12%, 30% and 34% above its estimates respectively — a clean beat on every line, not just one.

The margin maths: where the extra profit came from

The headline is the 64% profit jump, but the more useful number is the margin. For every ₹100 of sales this quarter, Divi's kept ₹30.66 as profit, against ₹25.38 a year ago. The EBITDA margin tells the same story: 42.60% this quarter against 32.71% a year ago (₹888 crore on ₹2,715 crore of revenue). Look at it a third way. Revenue grew by ₹961 crore year on year (₹3,676 crore minus ₹2,715 crore). Profit grew by ₹438 crore (₹1,127 crore minus ₹689 crore). So roughly 46 paise of every extra rupee of sales became profit — that is margin expansion doing the work, not just higher sales. One headwind sits inside the strong quarter. Foreign-exchange gains fell to ₹24 crore from ₹63 crore a year earlier. The profit jump happened despite a smaller currency tailwind, not because of one — which makes the operating improvement harder to dismiss.

Why the shares jumped 8% on a Sunday

Muhurat trading is a one-hour symbolic session — this year it ran from 2:20 PM to 3:30 PM IST on Sunday, 8 November — with thin volumes. That matters when reading the 8% move. The benchmarks ended the hour marginally lower: Sensex 80,999.40 (down 0.04%) and Nifty 24,986.40 (down 0.18%). It was the first time the benchmarks closed a Muhurat session in the red in nine years, and it snapped a seven-session winning streak. Yet beneath the flat headline, 2,716 stocks rose and the total market value of BSE-listed companies added about ₹2.6 lakh crore in the hour. Divi's was the session's standout because it had the day's clearest fresh news: results declared the previous day, a beat on every broker estimate, and a 52-week high as the trigger. A one-hour session with thin volumes can exaggerate a move in either direction. The 8% jump is a reaction to the results, not a verdict on the company.

What Divi's actually does

Divi's Laboratories makes active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients — the building blocks other drug makers use to manufacture finished medicines. Exports make up about 90% of its standalone sales revenue, so global demand matters more to Divi's than Indian domestic sales. Its global nutraceutical business recorded revenue of ₹571 crore in the first half of FY27, against ₹492 crore in the same period last year. That is the export story in one line: Indian-made drug ingredients sold to the world, with the rupee and overseas order books as the two variables that move the numbers most.

What it means for Indian readers

First, for anyone following pharma stocks: the quarter shows Indian API makers can grow fast when global orders pick up — revenue up 35% and margins wider at the same time. But one quarter is not a trend. Divi's has had soft quarters before, and a single strong result does not establish a new run-rate. Second, for everyone else: Divi's is a reminder that results, not headlines, move individual stocks. The market fell on Sunday and Divi's rose 8% on the same day, in the same hour. Index levels describe the average; company results describe the stock. Third, what this article does not do: it is not a buy or sell signal. A 52-week high after one strong quarter is a fact, not a recommendation. Margins of 42.6% are unusually high for a manufacturer and are worth watching — if they hold, the story strengthens; if they normalise, the next quarter looks very different.

What to watch next

The December quarter (Q3 FY27) is the test: whether the 42.6% operating margin holds, whether revenue growth stays above 30%, and what happens to foreign-exchange gains. Watch for broker estimate revisions after the Elara beat, and whether the share price holds above ₹11,000 in a normal full trading session on Monday — Muhurat moves often fade when regular volumes return.
What was Divi's Q2 FY27 net profit?
Why did Divi's shares jump 8% on 8 November 2026?
What does Divi's Laboratories do?
Does the 8% jump mean Divi's shares are a buy?

Ready to start?

Before reacting to a one-session 8% jump, read the company's Q2 filing — the numbers, not the move, are the story. Follow @myfwindia on Instagram for the daily checklist version of this guide. Get the myfw app on Google Play — 22+ calculators in your pocket.

Learn More
Educational content only — not financial advice. Consult a SEBI-registered investment adviser for personal guidance; investments are subject to market risk.
Sources: The Economic Times, 8 Nov 2026 15:43 IST; NDTV Profit, 7 Nov 2026; The Hindu BusinessLine, 7 Nov 2026; Divi's Laboratories Q2 FY27 earnings-call transcript (Roic.ai, 7 Nov 2026); company results filing to BSE/NSE, 7 Nov 2026.